Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
Express Scripts
Accenture
Boehringer Ingelheim
Moodys
US Department of Justice
Fish and Richardson
Federal Trade Commission

Generated: June 19, 2018

DrugPatentWatch Database Preview

EFFEXOR XR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Effexor Xr patents expire, and what generic alternatives are available?

Effexor Xr is a drug marketed by Wyeth Pharms Inc and is included in one NDA.

The generic ingredient in EFFEXOR XR is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.
Drug patent expirations by year for EFFEXOR XR
Medical Subject Heading (MeSH) Categories for EFFEXOR XR
Synonyms for EFFEXOR XR
(+-)-1-(alpha-((Dimethylamino)methyl)-p-methoxybenzyl)cyclohexanol hydrochloride
(+/-)-1-(alpha-((Dimethylamino)methyl)-p-methoxybenzyl)cyclohexanol hydrochloride
(+/-)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride
(R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloride
(RS)-1-(2-Dimethylamino-1-(4-methoxyphenyl)ethyl)cyclohexanol hydrochloride
(RS)-1-[2-(DIMETHYLAMINO)-1-(4-METHOXYPHENYL)ETHYL]CYCLOHEXANOL HYDROCHLORIDE
1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexan-1-ol hydrochloride
1-(2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol hydrochloride
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-1-cyclohexanol hydrochloride
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol hydrochloride
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol;hydrochloride
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, hcl
1-[2-Dimethylamino-1-(4-methoxy-phenyl)-ethyl]-cyclohexanol hydrochloride
1-[2-Dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexanol -HCl
93413-69-5 (Parent)
99300-78-4
A845995
AB0012466
AB2000111
AC-1696
AC1L1Y1S
AK326210
akos 92111
AKOS000280874
AKOS016340594
AN-14687
ANW-42650
API0004582
BC208275
BG0478
Bio-0110
BVF-012
C17H27NO2.HCl
CAS-99300-78-4
CCG-100979
CCG-213270
CHEBI:9944
CHEMBL1201066
CPD000469154
CS-2130
CTK5I0329
Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride
d,l-venlafaxine, hydrochloride
D00821
Dobupal
DSSTox_CID_27397
DSSTox_GSID_47397
DSSTox_RID_82318
DTXSID8047397
Efexor
Efexor XL
Effexor
Effexor (TN)
Effexor LP
Effexor XL
Effexor;Effexor XR;Efexor
FT-0642395
H13V695
HSDB 6699
HY-B0196A
I01-1036
J10231
KB-08072
KM3503
KS-00000WXA
KS-5049
LP00449
LS-57096
MCULE-5156532617
MFCD03658865
MLS001401454
MolPort-003-987-504
NC00229
NCGC00256703-01
NCGC00261134-01
NSC-745751
NSC745751
PF-00345408
PW-4112
QYRYFNHXARDNFZ-UHFFFAOYSA-N
s1441
SAM001246572
SC-23352
SCHEMBL41936
SMR000469154
TL8006063
Tox21_302508
Tox21_500449
TR-030420
Trevilor
Vandral
Venlafaxin HCL
Venlafaxine (hydrochloride)
Venlafaxine EA
Venlafaxine for system suitability, European Pharmacopoeia (EP) Reference Standard
VENLAFAXINE HCl
Venlafaxine Hydorchloride
venlafaxine hydro chloride
Venlafaxine hydrochloride
Venlafaxine hydrochloride (JAN/USAN)
Venlafaxine hydrochloride [USAN:USP]
Venlafaxine hydrochloride [USAN]
Venlafaxine Hydrochloride 1.0 mg/ml in Methanol (as free base)
Venlafaxine hydrochloride, >=98% (HPLC), powder
Venlafaxine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Venlafaxine Hydrochloride, pharmaceutical secondary standard; traceable to USP, PhEur
Venlafaxine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Venlafaxine XR
Venlafaxinehydrochloride
Wy 45030
Wy-45,030
Wy-45,030 Hcl; 9490-3
Wy-45030

US Patents and Regulatory Information for EFFEXOR XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-001 Oct 20, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-004 Oct 20, 1997 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-002 Oct 20, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-003 Oct 20, 1997 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for EFFEXOR XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-001 Oct 20, 1997 ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-004 Oct 20, 1997 ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-004 Oct 20, 1997 ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-004 Oct 20, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for EFFEXOR XR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 37.5 mg, 75 mg and 150 mg ➤ Subscribe 2007-05-03

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cipla
Johnson and Johnson
McKinsey
Federal Trade Commission
Medtronic
Citi
Cantor Fitzgerald
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.